Author

admin

Browsing

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Big pharma ETFs

Many of these funds have diverse holdings across some of the most important sectors in the pharmaceutical industry, including pain therapeutics, oncology, vaccines and biotechnology. Data was gathered on August 11, 2025.

1. iShares US Pharmaceuticals ETF (ARCA:IHE)

Total assets under management: US$539.44 million

Created on May 5, 2006, this iShares ETF tracks some of the top US pharma companies. In total, the iShares US Pharmaceuticals ETF has 41 holdings, with the vast majority being large-cap stocks.

Of its holdings, Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) are by far the largest portions in its portfolio, coming in at weightings of 25.51 percent and 17.68 percent, respectively. The next highest are Royalty Pharma (NASDAQ:RPRX) at 5.04 percent, Viatris (NASDAQ:VTRS) at 4.94 percent and Merck & Co (NYSE:MRK) at 4.59 percent.

2. VanEck Pharmaceutical ETF (NASDAQ:PPH)

Total assets under management: US$494.34 million

Established in late 2011, the VanEck Pharmaceutical ETF tracks the MVIS US Listed Pharmaceutical 25 Index. It has the capacity to provide big returns, even though there are some risks attached to the ETF. An analyst report indicates that investors looking for ‘tactical exposure’ to the pharma sector might consider this ETF as an investment option.

The ETF has 25 holdings, with the top five being Eli Lilly at a weight of 15.81percent, Johnson & Johnson at 12.08 percent, Novartis (NYSE:NVS) at 7.80 percent, Merck & Co. at 6.33 percent and Novo Nordisk (NYSE:NVO) at 5.94 percent.

3. Invesco Pharmaceuticals ETF (ARCA:PJP)

Total assets under management: US$240.1 million

The Invesco Pharmaceuticals ETF is primarily focused on providing exposure to US-based pharma companies. An analyst report states that this ETF chooses individual securities based on certain investment criteria, namely stock valuation and risk factors. Invesco changed the fund’s name from the Invesco Dynamic Pharmaceuticals ETF in August 2023.

This ETF was started on June 23, 2005, and currently tracks 31 companies. Its top holdings are Johnson & Johnson with a weight of 5.25 percent, Gilead Sciences (NASDAQ:GILD) at 5.08 percent, AbbVie (NYSE:ABBV) at 4.95 percent, and both Pfizer (NYSE:PFE) and Merck & Co. at 4.83 percent each.

4. SPDR S&P Pharmaceuticals ETF (ARCA:XPH)

Total assets under management: US$150.91 million

The SPDR S&P Pharmaceuticals ETF came into the market on June 19, 2006, and represents the pharmaceutical sub-industry sector of the S&P Total Markets Index. An analyst report for the ETF suggests that due to its narrow focus — which includes pharma giants that post ‘big returns’ during times of consolidation — it should not be considered for a long-term portfolio.

This pharma ETF tracks 43 holdings, with relatively close weighting among its holdings. XPH’s top five holdings are Elanco Animal Health (NYSE:ELAN) with a weight of 4.21 percent, Tarsus Pharmaceuticals (NASDAQ:TARS) with a weight of 4.18 percent, Johnson & Johnson at 4.02 percent, Royalty Pharma at 3.98 percent and Viatris at 3.89 percent.

5. KraneShares MSCI All China Health Care Index ETF

Total assets under management: US$111.67 million

The KraneShares MSCI All China Health Care Index ETF was launched in February 2018 and tracks an index of large- and mid-cap Chinese stocks in the healthcare sector, all weighted by market capitalization. According to an analyst report, the fund provides investors with ‘exposure to a relatively small slice of the Chinese economy.’

The ETF tracks 46 holdings, and its top five are BeOne Medicines at 8.26 percent, Jiangsu Hengrui Medicine (SHA:600276) at 8.24 percent, WuXi Biologics (HKEX:2269) at 6.71 percent, Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) at 5.95 percent and CSPC Pharmaceutical Group (HKEX:1093) at 5.39 percent.

Securities Disclosure: I, Meagen Seatter, hold no investment interest in any of the companies mentioned in this article.

This post appeared first on investingnews.com

Keith Weiner, founder and CEO of Monetary Metals, discusses gold and silver’s performance so far this year and shares his outlook for the rest of 2025.

He also explains what makes today’s gold bull market different than those seen in prior years.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ.

After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak of 4,954.813 on September 19, 2024. While the index had pulled back to 4,530.69 as of August 5, 2025, further growth could be in store in the future.

According to a Towards Healthcare analyst report, the global biotech market is expected to grow at a compound annual growth rate of 12.5 percent from now to 2034, reaching a valuation of US$5.04 trillion.

Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.

The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.

Data was gathered on August 5, 2025, using TradingView’s stock screener. Small-cap biotech stocks with market caps between US$50 million and US$500 million at that time were considered for this list.

1. Tiziana Life Sciences (NASDAQ:TLSA)

Year-to-date gain: 227.8 percent
Market cap: US$256.36 million
Share price: US$2.26

Tiziana Life Sciences is a clinical-stage biopharma which is developing therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its pipeline of candidates is built on its patent drug delivery technology that provides a possible alternative to intravenous delivery. Tiziana’s lead candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody.

Tiziana Life Sciences shares hit US$1.69 on March 7 after the company filed its investigational new drug application to the US Food and Drug Administration (FDA) for a Phase 2 clinical trial in amyotrophic lateral sclerosis (ALS), which is supported by the ALS Association. However, by early April that value had fallen back to US$0.78 per share.

A series of positive news flow later in the spring helped to give Tiziana shares another boost. In April, John Hopkins University and the University of Massachusetts commenced dosing of the biotech company’s intranasal foralumab in Phase 2 trials for patients with non-active secondary progressive multiple sclerosis. On May 7, the company shared positive results from the use of its lead candidate in improving the quality of life for patients with that form of multiple sclerosis.

Tiziana is also studying the use of intranasal foralumab for treating moderate Alzheimer’s disease. On May 9, it announced that PET scans of a patient with moderate Alzheimer’s showed a significant reduction in microglia activation associated with neuroinflammation after three months of treatment.

Shares of Tiziana reached US$1.62 on May 13.

On July 21, the company announced an ‘unexpected discovery’ in its findings of an immunologic analysis of the patient with Alzheimer’s disease.

‘In an unexpected discovery, the analysis revealed an increase in phagocytosis markers in classical monocytes, suggesting that nasal foralumab may enhance their ability to clear amyloid plaques,’ the press release states. ‘This unexpected effect may open new avenues for treating Alzheimer’s Disease by targeting both inflammation and amyloid accumulation.’

Tiziana’s share price climbed through the remainder of the month, hitting a year-to-date high of US$2.50 on July 31.

2. Palvella Therapeutics (NASDAQ:PVLA)

Year-to-date gain: 224.98 percent
Market cap: US$416.08 million
Share price: US$37.64

Palvella Therapeutics is a clinical-stage biopharma developing treatments targeting rare genetic skin diseases for which there are no FDA-approved therapies. The company’s product pipeline centers on its patented QTORIN platform, which has an initial focus on rare genetic skin diseases.

Its lead product candidate, QTORIN rapamycin, is currently in a Phase 2 clinical trial in cutaneous venous malformations, and a Phase 3 clinical trial in microcystic lymphatic malformations (LM). QTORIN rapamycin has been granted breakthrough therapy designation, orphan drug designation and fast track designation from the FDA for the treatment of microcystic LMs.

After starting the year at US$12.00, shares of Palvella had surged to US$20.99 by February 18. About a week earlier, the company had shared plans to expand the Phase 3 trial to include pediatric patients from three to five years of age. That momentum in Palvella’s share price continued to rally to US$29 per share on March 13.

June produced a number of significant milestones for Palvella. On June 9, the company received initial proceedings from a grant issued by the FDA Office of Orphan Products Development for its Phase 3 trial, and on June 23, it completed enrollment for the trial with 51 subjects, 25 percent over its target. The company closed out the month with news it was added to the broad-market Russell 3000 Index and the Russell 2000 Index.

The company said it remains on track to deliver top-line Phase 3 data in Q1 2026 to support its planned new drug application submission later that year.

While the company didn’t release news in July, Palvella Therapeutics’ share price climbed significantly through the month to hit a year-to-date high of US$39.87 on July 28.

3. OKYO Pharma (NASDAQ:OKYO)

Year-to-date gain: 163.03 percent
Market cap: US$117.35 million
Share price: US$3.13

OKYO Pharma is a clinical-stage biopharma developing therapies for the treatment of neuropathic corneal pain and dry eye disease. Its lead candidate is urcosimod, a non-steroidal anti-inflammatory and non-opioid analgesic.

So far in 2025, the company has achieved multiple milestones related to its Phase 2 trial of urcosimod for treatment of neuropathic corneal pain.

On April 30, OKYO announced plans to end the trial early to analyze the data from the patients who had completed the trial, with the goal of accelerating its clinical development and expanding the program. Supporting the decision was the fact that urcosimod had previously demonstrated safety in OKYO’s completed Phase 2 trial of the candidate to treat patients with dry eye disease.

The next day, news broke that the FDA granted urcosimod fast track designation for the treatment of neuropathic corneal pain. OKYO’s stock price reached US$1.57 on May 1.

On July 17, OKYO posted strong top-line data from its Phase 2 clinical trial, and stated it is planning a meeting with the FDA to discuss next steps for its lead drug candidate. The following day, OKYO received US$1.9 million in non-dilutive funding to support its clinical development of urcosimod.

Shares of OKYO hit a year-to-date high of US$3.17 on August 5.

4. IO Biotech (NASDAQ:IOBT)

Year-to-date gain: 129.47 percent
Market cap: US$144.28 million
Share price: US$2.16

IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating therapeutic cancer vaccines based on its T-win technology platform, designed to activate T cells to target both tumor cells and the immune-suppressive cells. The company’s lead cancer vaccine candidate IO102-IO103, which has the brand name Cylembio, is currently in clinical trials.

The FDA granted breakthrough therapy designation to IO102-IO103 when used in combination with Merck’s (NYSE:MRK) anti-PD-1 therapy KEYTRUDA for the treatment of advanced melanoma based on positive Phase 1/2 first line metastatic melanoma data.

At the start of the year, IO Biotech completed enrollment in its Phase 2 trial of IO102-IO103 with KEYTRUDA as a treatment given before and after surgery for resectable melanoma or head and neck cancer.

On February 4, the company published results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112, targeting arginase 1, which plays a key role in immune suppression.

In mid-March, IO Biotech was named to Fast Company’s list of the World’s Most Innovative Companies of 2025. The following month, the company presented new preclinical data for its lead candidate IO102-IO103 as well as IO170, which targets Transforming Growth Factor beta.

In its Q1 2025 financial results and business highlights released on May 14, IO Biotech shared that a readout of primary endpoint data from its pivotal Phase 3 trial of its lead investigational therapeutic cancer vaccine in patients with advanced melanoma is expected in the third quarter of 2025.

Shares of IO Biotech reached a year-to-date high of US$2.40 on July 28.

5. Spero Therapeutics (NASDAQ:SPRO)

Year-to-date gain: 110.95 percent
Market cap: US$124.12 million
Share price: US$2.22

Spero Therapeutics is developing novel treatments for rare diseases and multi-drug resistant bacterial infections with high unmet need. The company’s lead drug candidate is tebipenem pivoxil hydrobromide (HBr), a late-stage development asset developed in collaboration with pharma giant GSK (NYSE:GSK) to treat complicated urinary tract infections (cUTIs), including pyelonephritis.

Spero has an exclusive license agreement with GSK for the development and commercialization of the drug candidate in all ex-Asia markets. The FDA has granted tebipenem HBr qualified infectious disease product and fast track designations.

Shares in Spero traded below US$1.00 for much of the first half of 2025. However, the stock’s value surged 245 percent on May 28 to reach US$2.35 per share after Spero reported that its Phase 3 trial evaluating tebipenem HBr for treating cUTIs met its primary endpoint and stopped early for efficacy. GSK plans to include the findings in a filing to the FDA during H2.

Spero shares reached a year-to-date high of US$3.04 on July 9.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

(TheNewswire)

TORONTO, ON, August 13, 2025 TheNewswire – Silver Crown Royalties Inc. ( Cboe: SCRI,OTC:SLCRF; OTCQX: SLCRF; FRA: QS0) ( ‘Silver Crown’ or the ‘Company’ ) is pleased to announce that, further to its press release dated August 7, 2025, it has closed the acquisition of a royalty on 90% of the cash equivalent of silver produced each quarter from the past producing Scotia Mine (the ‘Silver Royalty’ ) with EDM Resources Inc. ( TSX-V: EDM; FSE: P3Z) ( ‘EDM’ ). The Silver Royalty provides for minimum of the cash equivalent of 7,000 ounces per year for 10 years starting at commercial production on the Scotia Mine. SCRi paid $250,000 in cash at closing and issued 60,000 units (‘ Units ‘) to EDM per Unit at a deemed value of C$10.00, with each Unit consisting of a common share in the capital of SCRi (‘ Common Share ‘) and one warrant exercisable into an additional Common Share at a price of C$13.00 for a period of 36 months following the date hereof. SCRi must pay EDM an additional C$250,000 cash payment following the date hereof as deferred consideration for the Silver Royalty.

ABOUT EDM RESOURCES INC.

EDM Resources Inc. (‘EDM’) ( TSX-V: EDM; FSE: P3Z) is a Canadian exploration and mining company that has full ownership of the Scotia Mine and related facilities near Halifax, Nova Scotia. Through its wholly owned subsidiary, EDM also holds several prospective exploration licenses near its Scotia Mine and in the surrounding regions of Nova Scotia .

ABOUT Silver Crown Royalties INC.

Founded by seasoned industry professionals, Silver Crown Royalties ( Cboe: SCRI | OTCQX: SLCRF | FRA: QS0) is a publicly traded silver royalty company dedicated to generating free cash flow. Silver Crown (SCRi) currently holds five silver royalties. Its business model offers investors exposure to precious metals, providing a natural hedge against currency devaluation while mitigating the adverse effects of production-related cost inflation. SCRi strives to minimize the economic burden on mining projects while simultaneously maximizing shareholder returns. For further information, please contact:

Silver Crown Royalties Inc.

Peter Bures, Chairman and CEO

Telephone: (416) 481-1744

Email: pbures@silvercrownroyalties.com

FORWARD-LOOKING STATEMENTS

This release contains certain ‘forward looking statements’ and certain ‘forward-looking information’ as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as ‘may’, ‘will’, ‘should’, ‘expect’, ‘intend’, ‘estimate’, ‘anticipate’, ‘believe’, ‘continue’, ‘plans’ or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements and information include, but are not limited to, SCRi must pay EDM an additional C$250,000 cash payment following the date hereof as deferred consideration for the Silver Royalty . Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual actions, events or results to be materially different from those expressed or implied by such forward-looking information, including but not limited to: the impact of general business and economic conditions; the absence of control over mining operations from which SCRi will purchase gold and other metals or from which it will receive royalty payments and risks related to those mining operations, including risks related to international operations, government and environmental regulation, delays in mine construction and operations, actual results of mining and current exploration activities, conclusions of economic evaluations and changes in project parameters as plans continue to be refined; accidents, equipment breakdowns, title matters, labor disputes or other unanticipated difficulties or interruptions in operations; SCRi’s ability to enter into definitive agreements and close proposed royalty transactions; the inherent uncertainties related to the valuations ascribed by SCRi to its royalty interests; problems inherent to the marketability of gold and other metals; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; industry conditions, including fluctuations in the price of the primary commodities mined at such operations, fluctuations in foreign exchange rates and fluctuations in interest rates; government entities interpreting existing tax legislation or enacting new tax legislation in a way which adversely affects SCRi; stock market volatility; regulatory restrictions; liability, competition, the potential impact of epidemics, pandemics or other public health crises on SCRi’s business, operations and financial condition, loss of key employees. SCRi has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. SCRi undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available.

This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities of the Company in Canada, the United States or any other jurisdiction. Any such offer to sell or solicitation of an offer to buy the securities described herein will be made only pursuant to subscription documentation between the Company and prospective purchasers. Any such offering will be made in reliance upon exemptions from the prospectus and registration requirements under applicable securities laws, pursuant to a subscription agreement to be entered into by the Company and prospective investors. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

CBOE CANADA DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Copyright (c) 2025 TheNewswire – All rights reserved.

News Provided by TheNewsWire via QuoteMedia

This post appeared first on investingnews.com

Disney’s ESPN and Fox Corp. are teaming up to offer their upcoming direct-to-consumer streaming services as a bundle, the companies said Monday.

The move comes as media companies look to nab more consumers for their streaming alternatives, and draw them in with sports, in particular.

Last week, both companies announced additional details about the new streaming options. ESPN’s streaming service — which has the same name as the TV network — and Fox’s Fox One will each launch on Aug. 21, ahead of the college football and NFL seasons.

The bundled apps, however, will be available beginning Oct. 2 for $39.99 per month. Separately, ESPN and Fox One will cost $29.99 and $19.99 a month, respectively.

While the bundle will offer sports fans a bigger offering at a discounted rate, the streaming services are not exactly the same.

ESPN’s flagship service will be an all-in-one app that includes all of its live sports and programming from its TV networks, including ESPN2 and the SEC Network, as well as ESPN on Disney-owned ABC. The app will also have fantasy products, new betting tie-ins, studio programming and documentaries.

ESPN will also offer its app as a bundle with Disney’s other streaming services, Disney+ and Hulu, for $35.99 a month. That Disney bundle will cost a discounted $29.99 a month for the first 12 months — the same price as the stand-alone app.

Last week, ESPN further beefed up the content on its streaming app when it inked a deal with the WWE for the U.S. rights to the wrestling league’s biggest live events, including WrestleMania, the Royal Rumble and SummerSlam, beginning in 2026. The sports media giant also reached an agreement with the NFL that will see ESPN acquire the NFL Network and other media assets from the league.

The Fox One service, however, will be a bit different. Fox had been on the sidelines of direct-to-consumer streaming for years after its competitors launched their platforms. Just this year, it said it would offer all of its content — including news and entertainment — from its broadcast and pay TV networks in a streaming offering. Fox One won’t have any exclusive or original content.

Fox’s move into the direct-to-consumer streaming game — outside of its Fox Nation app and the free, ad-supported streamer Tubi — came after it abandoned its efforts to launch Venu, a joint sports streaming venture with Disney and Warner Bros. Discovery.

Both Fox CEO Lachlan Murdoch and Disney CEO Bob Iger said during separate earnings calls last week that they were exploring bundling options with other services. Since Fox announced the Fox One app, Murdoch has said the company would lean into bundles with other streaming services.

“Announcing ESPN as our first bundle partner is evidence of our desire to deliver the best possible value and viewing experience to our shared customers,” said Tony Billetter, SVP of strategy and business development for FOX’s direct to consumer segment, in a release on Monday.

This post appeared first on NBC NEWS

Generative artificial intelligence (AI) has helped a group of scientists identify five new materials that could power the next wave of batteries without relying on lithium.

The study, published on June 26 in Cell Reports Physical Science, focuses on materials that could enable multivalent-ion batteries — a technology long touted for its potential, but hindered by practical challenges.

The lithium problem for batteries

Lithium dominates in batteries used in everything from smartphones to electric vehicles, but faces challenges — it is costly to extract, geographically concentrated and comes with environmental and geopolitical concerns.

As global demand for batteries surges, researchers are racing to find viable alternatives that are both abundant and efficient. Multivalent-ion batteries offer one potential path forward. Unlike lithium-ion batteries, which carry a single positive charge, multivalent-ion batteries using materials like magnesium or zinc carry two or three.

In theory, this means that they can pack more energy into the same space. However, their larger size and stronger charge make it difficult for them to move through standard battery materials.

“One of the biggest hurdles wasn’t a lack of promising battery chemistries — it was the sheer impossibility of testing millions of material combinations,” said lead author Dibakar Datta, a professor of mechanical and industrial engineering at the New Jersey Institute of Technology. “We turned to generative AI as a fast, systematic way to sift through that vast landscape and spot the few structures that could truly make multivalent batteries practical.”

To tackle the challenge, Datta’s team developed a “dual AI” system. The first part, a crystal diffusion variational autoencoder (CDVAE), was trained on vast datasets of known crystal structures. It could generate entirely new porous transition metal oxides, a class of material known for its structural flexibility and ionic conductivity.

The second part was a fine-tuned large language model (LLM) designed to narrow the list.

It focused on materials closest to thermodynamic stability, a critical factor in determining whether a compound can realistically be made and used in the real world.

The CDVAE cast a wide net, creating thousands of hypothetical structures with large, open channels. The LLM then acted as a filter, selecting only those most likely to hold up under actual manufacturing and operational conditions.

Five new battery candidates

“Our AI tools dramatically accelerated the discovery process, which uncovered five entirely new porous transition metal oxide structures that show remarkable promise,” Datta said.

These structures, the study suggests, offer unusually large pathways for ion movement, a crucial step toward making multivalent batteries that charge quickly and last for long periods of time. Quantum mechanical simulations and stability tests confirmed that the materials should be both synthetically feasible and structurally sound.

The five compounds now move to the next stage — experimental synthesis in collaboration with partner laboratories. If successful, they could be incorporated into prototype batteries and eventually scaled for commercial production.

Traditional materials research is often a painstaking, years-long process of hypothesis, synthesis and testing.

By contrast, AI can rapidly explore enormous “material spaces” that would be impossible for humans to search manually, flagging only the most promising candidates for further investigation.

What it means for the batteries of tomorrow

Multivalent-ion batteries have been studied for decades, yet few have reached commercial readiness because the necessary materials either didn’t conduct ions well enough or degraded too quickly.

By using AI to overcome that bottleneck, the research team hopes to accelerate not just battery chemistry, but also the infrastructure needed to support electrification on a global scale.

However, the five materials identified by Datta’s team aren’t ready to replace lithium tomorrow. They still need to be synthesized, tested in lab-scale batteries and proven to perform under real-world conditions.

Safety, scalability and cost effectiveness all remain open questions.

Still, the study’s authors argue that their AI framework has already proven its value by shrinking what could have been a decades-long search into a matter of months.

“This is more than just discovering new battery materials — it’s about establishing a rapid, scalable method to explore any advanced materials, from electronics to clean energy solutions, without extensive trial and error,” Datta added.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Strong demand in the face of looming supply shortages has pushed copper to new heights in recent years.

With a wide range of applications in nearly every sector, copper is by far the most industrious of the base metals. In fact, for decades, the copper price has been a key indicator of global economic health, earning the red metal the moniker “Dr. Copper.” Rising prices tend to signal a strong global economy, while a significant longer-term drop in the price of copper is often a symptom of economic instability.

After bottoming out at US$2.17 per pound, or US$5,203.58 per metric ton (MT), in mid-March 2020, copper has largely been on an upward trajectory.

Why is copper so expensive in 2025? Higher copper prices over the past few years have largely been attributed to a widening supply/demand gap. The already tenuous copper supply picture was made worse by COVID-19 lockdowns, and as the world’s largest economies seemingly began to emerge from the pandemic, demand for the metal picked up once again. Copper mining and refining activities simply haven’t kept up with the rebound in economic activity.

In this article

    What key factors drive the price of copper?

    Robust demand has long been one of the strongest factors driving copper prices. The ever-growing number of copper uses in everyday life — from building construction and electrical grids to electronic products and home appliances — make it the world’s third most-consumed metal.

    Copper’s anti-corrosive and highly conductive properties are why it’s the go-to metal for the construction industry, and it’s used in products such as copper pipes and copper wiring. In fact, construction is responsible for nearly half of global copper consumption. Rising demand for new homes and home renovations in both Asian and Western economies is expected to support copper prices in the long term.

    In recent decades, copper price spikes have been strongly tied to rising demand from China as the economic powerhouse injects government-backed funding into new housing and infrastructure. Industrial production and construction activity in the Asian nation have been like rocket fuel for copper prices.

    Additionally, copper’s conductive properties are increasingly being sought after for use in renewable energy applications, including thermal, hydro, wind and solar energy.

    However, the biggest driver of copper consumption in the renewable energy sector is rising global demand for electric vehicles (EVs), EV charging infrastructure and energy storage applications. As governments push forward with transportation network electrification and energy storage initiatives as a means to combat climate change, copper demand from this segment is expected to surge.

    New energy vehicles use significantly more copper than internal combustion engine vehicles, which only contain about 22 kilograms of copper. In comparison, hybrid EVs use an average of 40 kilograms, plug-in hybrid EVs use 55 kilograms, battery EVs use 80 kilograms and battery electric buses use 253 kilograms.

    In 2024, EV sales worldwide increased by 25 percent over 2023 to come in at about 17.1 million units, and analysts at Rho Motion expect that trend to continue in the coming years despite some headwinds in the near-term. Already in the first five months of 2025, EV sales were up 28 percent over the same period in the previous year.

    On the supply side of the copper market, the world’s largest copper mines are facing depleting high-grade copper resources, while over the last decade or more new copper discoveries have become few and far between.

    The pandemic made the situation worse as mining activities in several top copper-producing countries faced work stoppages and copper companies delayed investments in further exploration and development — a challenging problem considering it can take as many as 10 to 20 years to move a project from discovery to production. In addition, delayed investments amid the pandemic will also have long-term repercussions for copper supply.

    There have also been ongoing production issues at major copper mines, most notably the shutdown in late 2023 of First Quantum Minerals’ (TSX:FM,OTC Pink:FQVLF) Cobre Panama mine, which accounted for about 350,000 MT of the world’s annual copper production.

    The International Energy Agency (IEA) is forecasting a 30 percent shortfall in the amount of copper needed to meet demand by 2035. “This will be a major challenge. It’s time to sound the alarm,” IEA Executive Director Fatih Birol said.

    The supply shortage has increased the need for end users to turn to the copper scrap market to make up for the supply shortage. Sometimes referred to as “the world’s largest copper mine,” recycled copper scrap contributes significantly to supplying and balancing the copper market.

    “We are seeing signs this could change. Much of the growth over the last five years has come from brownfield expansions rather than greenfield/new discoveries,’ she said. ‘Technology will likely help increase the chance of discovery, and broadly I would say that policymakers are now more supportive of mineral exploration as the push to secure critical raw materials supply has moved up the agenda.’

    Joannides offered some examples of greenfield projects in the pipeline: Capstone Copper’s (TSX:CS,OTC Pink:CSCCF) Santo Domingo in Chile, Southern Copper’s (NYSE:SCCO) Tia Maria in Peru and Teck Resources’ (TSX:TECK.A,TECK.B,NYSE:TECK) Zafranal in Peru.

    How has the copper price moved historically?

    Taking a look back at historical price action, the copper price has had a wild ride for more than two decades.

    Sitting at US$1.38 per pound in late January 2005, the copper price followed global economic growth up to a high of US$3.91 in April 2008. Of course, the global economic crisis of 2008 soon led to a copper crash that left the metal at only US$1.29 by the end of year.

    Once the global economy began to recover in 2011, copper prices posted a new record high of US$4.58 per pound at the start of the year. However, this high was short-lived as the copper price began a five year downward trend, bottoming out at around US$1.95 in early 2016.

    Copper prices stayed fairly flat over the next four years, moving in a range of US$2.50 to US$3 per pound.

    20 year copper price performance.

    Chart via Macrotrends.

    The pandemic’s impact on mine supply and refined copper in 2020 pushed prices higher despite the economic slowdown. The copper price climbed from a low of US$2.17 in March to close out the year at US$3.52.

    In 2021, signs of economic recovery and supercharged interest in EVs and renewable energy pushed the price of copper to rally higher and higher. Copper topped US$4.90 per pound for the first time ever on May 10, 2021, before falling back to close at US$4.76.

    Also affecting the copper price at that time was expectations for higher copper demand amid supply concerns out of two of the world’s major copper producers: Chile and Peru. In late April 2021, port workers in Chile called for a strike, while in Peru presidential candidate Pedro Castillo proposed nationalizing mining and redrafting the country’s constitution.

    In early May 2021, news broke that copper inventories were at their lowest point in 15 years. Expert market watchers such as Bank of America commodity strategist Michael Widmer warned that further inventory declines into 2022 could lead to a copper market deficit.

    After climbing to start 2022 at US$4.52, the copper price continued to spike on economic recovery expectations and supply shortages to reach US$5.02 per pound on March 6. Throughout the first quarter, fears of supply chain disruptions and historically low stockpiles amid rising copper demand drove prices higher.

    However, copper prices pulled back in mid-2022 on worries that further COVID-19 lockdowns in China, as well as a growing mortgage crisis, would slow down construction and infrastructure activity in the Asian nation. Rising inflation and interest hikes by the Fed also placed downward pressure on a wide basket of commodities, including copper. By late July 2022, copper prices were trading down at nearly a two year low of around US$3.30.

    In the early months of 2023 the copper price was trading over the US$4 per pound level after receiving a helpful boost from continuing concerns about low copper inventories, signs of rebounding demand from China, and news about the closure of Peru’s Las Bambas mine, which accounts for 2 percent of global copper production.

    However, that boost turned to a bust in the second half of 2023 as China continued to experience real estate sector issues, alongside the economic woes of the rest of the world. The price of copper dropped to a low for the year of US$3.56 per pound in mid October.

    Elevated supply levels kept copper trading in the US$3.50 to US$3.80 range for much of Q1 2024 before experiencing strong gains that pushed the price of the red metal to US$4.12 on March 18.

    Those gains were attributed to in part to tighter copper concentrate supply following the closure of First Quantum Minerals’ Cobre Panama mine, guidance cuts from Anglo American (LSE:AAL,OTCQX:AAUKF) and declining production at Chile’s Chuquicamata mine. In addition, China’s top copper smelters announced production cuts after limited supply led to lower profits from treatment and refining charges.

    BHP’s (ASX:BHP,NYSE:BHP,LSE:BHP) attempted takeover of Anglo American also stoked fears of even tighter global copper mine supply. These supply-side challenges continued to juice copper prices in Q2 2024, causing a jump of nearly 29 percent from US$4.04 per pound on April 1 to a then all-time high of US$5.20 by May 20, 2024.

    What was the highest price for copper ever?

    The price of copper reached its highest recorded price of US$5.959 per pound, or US$13,137.75 per metric ton, on July 24, 2025. It hit this peak during intra-day trading before closing the day at US$5.88. The red metal’s price surged more than 17 percent since the start of July to its new all time high. Read on to found out how the copper price reached those heights.

    Why did the copper price hit an all-time high in 2025?

    After starting 2025 at US$3.99 per pound, copper prices were lifted in Q1 by increasing demand from China’s economic stimulus measures, renewable energy and artificial intelligence (AI) technologies and stockpiling brought on by fear of US President Trump’s tariff threats.

    At the time, Trump had said the US was considering placing tariffs of up to 25 percent on all copper imports in a bid to spark increased domestic production of the base metal.

    In late February, he signed an executive order instructing the US Commerce Department to investigate whether imported copper poses a national security risk under Section 232 of the Trade Expansion Act of 1962. The price of copper reached a new high price of US$5.24 per pound on March 26 as tariff tensions escalated.

    Trump’s tariff talk sparked yet another copper price rally to set its new record high price in early July when he announced he plans to impose a 50 percent tariff on all imports of the red metal, and it moved higher towards the end of the month in anticipation of them entering effect.

    However, copper’s price plummeted from its heights on July 31 following the reveal that tariffs would not be imposed on imports of raw or refined copper, instead targeting semi-finished copper products.

    Looking at the bigger picture, copper’s rally in recent years has encouraged bullish sentiment on prices looking ahead. In the longer term, the fundamentals for copper are expected to get tighter as demand increases from sectors such as EVs and energy storage. A May 2024 report from the International Energy Forum (IEF) projects that as many as 194 new copper mines may need to come online by 2050 to support massive demand from the global energy transition.

    Looking over to renewable energy, according to the Copper Development Association, solar installations require about 5.5 MT of copper for every megawatt, while onshore wind turbines require 3.52 MT of copper and offshore wind turbines require 9.56 MT of copper.

    The rise of AI technology is also bolstering the demand outlook for copper. Commodities trader Trafigura has said AI-driven data centers could add one million MT to copper demand by 2030, reports Reuters.

    Where can investors look for copper opportunities?

    Copper market fundamentals suggest a return to a bull market cycle for the red metal in the medium-term. The copper supply/demand imbalance also presents an investment opportunity for those interested in copper-mining stocks.

    Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

    This post appeared first on investingnews.com

    Lithium, a naturally occurring trace element in the brain, may be able to unlock a key medical mystery: why some people develop Alzheimer’s disease and others don’t, despite similar brain changes.

    In a recently published study, scientists at Harvard Medical School state that lithium not only exists in the human brain at biologically meaningful levels, but also appears to protect against neurodegeneration.

    Additionally, their work shows that lithium supports the function of all major brain cell types.

    The decade-long study drew on mouse experiments and analyses of human brain and blood samples across the spectrum of cognitive health. The Harvard team discovered that as amyloid beta, the sticky protein associated with Alzheimer’s, begins to accumulate, it binds to lithium and depletes its availability in the brain. This drop in lithium impairs neurons, glial cells and other brain structures, accelerating memory loss and disease progression.

    “The idea that lithium deficiency could be a cause of Alzheimer’s disease is new and suggests a different therapeutic approach,” said Bruce Yankner, who is the senior author of the study.

    Yankner, a professor of genetics and neurology at Harvard Medical School who in the 1990s was the first to show that amyloid beta is toxic to nerve cells, said the new findings open the door to treatments that address the disease in its entirety, rather than targeting single features like amyloid plaques or tau tangles.

    To explore this possibility, researchers screened for lithium compounds that could evade capture by amyloid beta.

    They identified lithium orotate as the most promising candidate. In mice, the compound reversed Alzheimer’s-like brain changes, prevented cell damage and restored memory, even in animals with advanced disease.

    Crucially, the effective dose was about one-thousandth of that used in psychiatric treatments, avoiding the toxicity risk that has hampered lithium’s clinical use in older patients.

    “You have to be careful about extrapolating from mouse models, and you never know until you try it in a controlled human clinical trial,” Yankner cautioned. “But so far the results are very encouraging.”

    The path to these findings began with access to an unusually rich source of brain tissue.

    Working with the Rush Memory and Aging Project in Chicago, the team examined postmortem samples from thousands of donors, from cognitively healthy individuals to those with mild cognitive impairment and full-blown Alzheimer’s.

    Using advanced mass spectrometry, they measured trace levels of about 30 metals. Lithium stood out as the only one whose levels dropped sharply at the earliest stages of memory loss.

    The pattern matched earlier population studies linking higher environmental lithium levels, including in drinking water, to lower dementia rates. But unlike those correlations, the Harvard team directly measured brain lithium and established a normal range for healthy individuals who had never taken lithium as medication.

    “Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C,” Yankner said. “It’s the first time anyone’s shown that lithium exists at a natural level that’s biologically meaningful without giving it as a drug.”

    To test whether this deficiency was more than an association, the researchers fed healthy mice a lithium-restricted diet, lowering brain lithium to levels seen in Alzheimer’s patients.

    The animals developed brain inflammation, lost connections between neurons and showed cognitive decline; however, replenishing them with lithium orotate reversed these changes. What’s more, mice given the compound from early adulthood were protected from developing Alzheimer’s-like symptoms altogether.

    The findings raise several possibilities. Measuring lithium levels in blood could become a tool for early screening, identifying people at risk before symptoms emerge. Furthermore, amyloid-evading lithium compounds could be tested as preventive or therapeutic agents, potentially altering the disease course more fundamentally than existing drugs.

    For now, researchers stress that no one should self-medicate with lithium supplements.

    The team emphasized that the safety and efficacy of lithium orotate in humans remain unproven, and clinical trials will be needed to determine whether the dramatic benefits seen in mice translate to people.

    Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

    This post appeared first on investingnews.com